SIU 2017: Recirculative Neoadjuvant Chemohyperthermia in NMIBC Patients
Lisbon, Portugal (UroToday.com) The authors presented a study where they reviewed the safety and efficacy of neoadjuvant Hyperthermic Intra-VEsical Chemotherapy (“HIVEC"), delivered with the COMBAT system in a group of patients with intermediate or high risk non-muscle invasive bladder cancer (NMIBC).
SIU 2017: En BIOC Transurethral Resection with Hybrid Knife for Treatment of Primary Non-Muscle-Invasive Bladder Cancer: A Single-Center, Randomized, Controlled Trial
Lisbon, Portugal (UroToday.com) Dr. Hu presented a study attempting to evaluate the safety and effectivity of en bloc transurethral resection with Hybrid Knife as a treatment for primary non-muscle-invasive bladder cancer (NMIBC), and compare it to conventional transurethral resection of bladder tumor (TURBT).
SIU 2017: Association between Pre-Cystectomy Epithelial Tumor Marker Response to Neoadjuvant Chemotherapy and Oncological Outcomes in Urothelial Bladder Cancer
Lisbon, Portugal (UroToday.com) The authors previously reported that elevated pre-cystectomy serum levels of epithelial tumor markers predict worse oncological outcome in patients with invasive bladder cancer (BC). In this study, the authors evaluated the effect of neoadjuvant chemotherapy (NAC) on elevated tumor marker levels and their association with oncological outcomes.
SIU 2017: Are We Subjecting Too Many Patients to an Early Re-Resection?
Lisbon, Portugal (UroToday.com) Early TURBT re-resection is recommended for incomplete primary resections, large or multiple tumours, the presence of high-grade disease, or the absence of muscle in the specimen. Current evidence in high-grade disease shows residual disease in 33-53%, with upstaging to muscle-invasive disease in 4-25%. The objective of the authors in this study was to investigate patients diagnosed with high-grade bladder cancer with muscle in the specimen, and assess if they may benefit more from commencing intravesical BCG over early re-resection.
SIU 2017: Intravesical Immunomodulatory lmiquimod Enhances Bacillus Calmette Guérin (BCG) Down Regulation of Non-muscle invasive Bladder Cancer
Lisbon, Portugal (UroToday.com) Bacillus Calmette-Guérin (BCG) although not failure proof, has been the most efficient immunomodulatory treatment in the immunogenic non-muscle invasive bladder cancer (NMIBC) for the past 40 years. The authors investigated the role of immunomodulatory molecule Imiquimod through the main downstream molecules of mammalian Target of Rapamycin (mTOR) pathway and the BCG key receptors TLR 2 and TLR4 in NMIBC treatment.
SIU 2017: The Role of Vitamin D Receptor Polymorphisms in Predicting Response to Therapy in Non-Muscle Invasive Bladder Carcinoma
Lisbon, Portugal (UroToday.com) Clinico-pathological factors predicting for response to Bacillus-Calmette Guerin (BCG) treatment for non-muscle invasive bladder carcinoma (NMIBC) are well defined but there is a paucity of data on genetic factors. Vitamin D has been found to have immunomodulatory effects in pre-clinical bladder cancer studies. Various single nucleotide polymorphisms (SNP) of the Vitamin D Receptor (VDR) gene have also been found to be associated with response to treatment for mycobacterium.
SIU 2017: Intraoperative Frozen Section Evaluation of the Tumor and its Base in Patients with T1 Urothelial Bladder Cancer
Lisbon, Portugal (UroToday.com) While transurethral resection of bladder tumor (TURBT) remains the main surgical procedure for non-muscle invasive bladder cancer, there is evidence of a high rate of under-staging for T1 disease after primary resection. Although presence of muscle is mandatory for staging purposes, nearly 40% of resected bladder specimens in TURBT do not contain muscle. Dr. Shen presented a study prospectively investigating the tumor base resected in TURBTs and whether muscle was present in the specimen using frozen section examination.